Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 28, 2026Blood AdvancesOpen Access

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic

View Full Paper
Ask AI
Bookmark
Share

Authors

PVProkop VodičkaAJAndrea JaníkováKPKamila Polgárová

Discussion

Loading...

Member takes

Overview

Randomized trial reveals improved overall survival with third-line therapies in diffuse large B-cell lymphoma, suggesting benefits from integrating novel treatments.

Key Points

  • To assess temporal changes in overall survival and clinical response rates among patients with relapsed or refractory diffuse large B-cell lymphoma treated with third-line therapy across two distinct eras.
  • Evaluated 312 consecutive patients with relapsed/refractory diffuse large B-cell lymphoma receiving third-line therapy from the prospective NiHiL project (NCT03199066) in the Czech Republic.
  • Categorized patients into two treatment periods according to CAR-T access: Era 1 (2018–2020, n=134) and Era 2 (2021–2023, n=178) to evaluate overall survival, event-free survival, response rates, and treatment patterns.
  • Overall survival was significantly higher in Era 2 versus Era 1 (HR=0.70, P=0.01), with 2-year overall survival rates reaching 43% compared to 29%.
  • Two-year event-free survival improved from 13% in Era 1 to 24% in Era 2 (HR=0.70, P=0.01), alongside an increase in complete remission rates from 18% to 30% (P=0.02).
  • CAR-T therapy uptake increased from 6% to 32% and novel agent use rose from 13% to 22% (P<0.01), with the most pronounced survival benefits seen in the CAR-T-eligible cohort (n=202).

Cite This Study

Vodička et al. (2026) studied this question.

synapsesocial.com/papers/6a91467bd15324a1df3aa2aahttps://doi.org/10.1182/bloodadvances.2026020000
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis2025
  2. 2Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database2025
  3. 3Outcomes in relapsed/refractory diffuse large B-cell lymphoma in an Asian tertiary cancer center: contemporary interventions as a benchmark for novel therapy2025
  4. 4Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The <scp>STRIDER</scp> study2024 · 12 citations
  5. 5Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy2024 · 18 citations